28428488|t|Improvement in Exercise Capacity by Exercise Training Associated With Favorable Clinical Outcomes in Advanced Heart Failure With High B-Type Natriuretic Peptide Level
28428488|a|The efficacy of exercise training (ET) programs and its relationship with long-term clinical outcomes in advanced heart failure (HF) patients with high levels of B-type natriuretic peptide (BNP) remain uncertain.Methods and Results:We studied 340 consecutive HF patients with ejection fraction (EF) <45% who completed a 3- month ET program. Patients with BNP ≥200 pg/mL (High - BNP, n=170) had more advanced HF characteristics, including lower EF (25.0±8.6% vs. 28.1±8.0%, P=0.0008), than those with BNP <200 pg/mL. In the High - BNP patients, peak oxygen uptake (V̇O2) was significantly increased by 8.3±16.2% during the ET program, and changes in peak V̇O2 inversely correlated with changes in BNP (R=-0.453, P<0.0001) and changes in ventilatory efficiency (V̇E / V̇CO2 slope) (R=-0.439, P<0.0001). During a median follow-up of 46 months, patients in the upper tertile of changes in peak V̇O2 (≥13.0%), compared with those in the lower tertile (<1.0%), had lower rates of the composite of all-cause death or HF hospitalization (37.9% vs. 54.4%, P=0.036) and all-cause death (8.6% vs. 24.6%, P=0.056). In the multivariate analysis, change in peak V̇O2 was a significant independent predictor of the composite outcome and all-cause death. Even among advanced HF p atient s with high BNP level, an ET program significantly improved exercise capacity, and a greater improvement in exercise capacity was associated with greater decreases in BNP level and V̇E / V̇CO2 slope and more favorable long-term clinical outcomes.
28428488	0	11	Improvement	T077	C2986411
28428488	15	32	Exercise Capacity	T081	C1516240
28428488	36	53	Exercise Training	T056	C4279936
28428488	54	69	Associated With	T080	C0332281
28428488	70	97	Favorable Clinical Outcomes	T033	C1333602
28428488	101	123	Advanced Heart Failure	T047	C0018801
28428488	129	133	High	T080	C0205250
28428488	134	160	B-Type Natriuretic Peptide	T116,T121,T125	C0054015
28428488	171	179	efficacy	T080	C1280519
28428488	183	200	exercise training	T056	C4279936
28428488	202	204	ET	T056	C4279936
28428488	206	214	programs	T169	C3484370
28428488	223	235	relationship	T080	C0439849
28428488	241	250	long-term	T079	C0443252
28428488	251	268	clinical outcomes	T080	C0085415
28428488	272	294	advanced heart failure	T047	C0018801
28428488	296	298	HF	T047	C0018801
28428488	300	308	patients	T101	C0030705
28428488	314	318	high	T080	C0205250
28428488	319	325	levels	T080	C0441889
28428488	329	355	B-type natriuretic peptide	T116,T121,T125	C0054015
28428488	357	360	BNP	T116,T121,T125	C0054015
28428488	402	409	studied	T062	C2603343
28428488	414	425	consecutive	T080	C1707491
28428488	426	428	HF	T047	C0018801
28428488	429	437	patients	T101	C0030705
28428488	443	460	ejection fraction	T060	C0489482
28428488	462	464	EF	T060	C0489482
28428488	475	484	completed	T080	C0205197
28428488	490	495	month	T079	C0439231
28428488	496	498	ET	T056	C4279936
28428488	499	506	program	T169	C3484370
28428488	508	516	Patients	T101	C0030705
28428488	522	525	BNP	T116,T121,T125	C0054015
28428488	538	542	High	T080	C0205250
28428488	545	548	BNP	T116,T121,T125	C0054015
28428488	566	574	advanced	T079	C3854260
28428488	575	577	HF	T047	C0018801
28428488	578	593	characteristics	T080	C1521970
28428488	605	613	lower EF	T033	C0743400
28428488	667	670	BNP	T116,T121,T125	C0054015
28428488	690	694	High	T080	C0205250
28428488	697	700	BNP	T116,T121,T125	C0054015
28428488	701	709	patients	T101	C0030705
28428488	711	729	peak oxygen uptake	T033	C0429693
28428488	731	735	V̇O2	T033	C0429693
28428488	755	764	increased	T081	C0205217
28428488	789	791	ET	T056	C4279936
28428488	792	799	program	T169	C3484370
28428488	805	812	changes	T169	C0392747
28428488	816	825	peak V̇O2	T033	C0429693
28428488	836	846	correlated	T080	C1707520
28428488	852	859	changes	T169	C0392747
28428488	863	866	BNP	T116,T121,T125	C0054015
28428488	892	899	changes	T169	C0392747
28428488	903	925	ventilatory efficiency	T081	C0013682
28428488	927	930	V̇E	T081	C0013682
28428488	933	938	V̇CO2	T033	C0429247
28428488	984	993	follow-up	T058	C1522577
28428488	1000	1006	months	T079	C0439231
28428488	1008	1016	patients	T101	C0030705
28428488	1030	1037	tertile	T080	C0205556
28428488	1041	1048	changes	T169	C0392747
28428488	1052	1061	peak V̇O2	T033	C0429693
28428488	1072	1080	compared	T052	C1707455
28428488	1105	1112	tertile	T080	C0205556
28428488	1132	1137	rates	T081	C1521828
28428488	1145	1154	composite	T080	C0205199
28428488	1168	1173	death	T040	C0011065
28428488	1177	1179	HF	T047	C0018801
28428488	1180	1195	hospitalization	T058	C0019993
28428488	1237	1242	death	T040	C0011065
28428488	1277	1298	multivariate analysis	T081	C0026777
28428488	1300	1306	change	T169	C0392747
28428488	1310	1319	peak V̇O2	T033	C0429693
28428488	1326	1337	significant	T078	C0750502
28428488	1350	1359	predictor	T078	C2698872
28428488	1367	1376	composite	T080	C0205199
28428488	1377	1384	outcome	T169	C1274040
28428488	1399	1404	death	T040	C0011065
28428488	1426	1428	HF	T047	C0018801
28428488	1431	1437	atient	T101	C0030705
28428488	1445	1449	high	T080	C0205250
28428488	1450	1453	BNP	T116,T121,T125	C0054015
28428488	1454	1459	level	T080	C0441889
28428488	1464	1466	ET	T056	C4279936
28428488	1467	1474	program	T169	C3484370
28428488	1489	1497	improved	T033	C0184511
28428488	1498	1506	exercise	T056	C0015259
28428488	1507	1515	capacity	T081	C1516240
28428488	1531	1542	improvement	T077	C2986411
28428488	1546	1554	exercise	T056	C0015259
28428488	1555	1563	capacity	T081	C1516240
28428488	1568	1583	associated with	T080	C0332281
28428488	1592	1601	decreases	T033	C0442797
28428488	1605	1608	BNP	T116,T121,T125	C0054015
28428488	1609	1614	level	T080	C0441889
28428488	1619	1622	V̇E	T081	C0013682
28428488	1625	1630	V̇CO2	T033	C0429247
28428488	1646	1683	favorable long-term clinical outcomes	T033	C1333602